Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A

Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A Tammaryn Lashley Maria-Armineh Tossounian Neve Costello Heaven Samantha Wallworth Sew Peak-Chew Aaron Bradshaw J. Mark Cooper Rohan de Silva Surjit Kaila Srai Oksana Malanchuk Valeriy Filonenko Margreet B. Koopman Stefan G. D. Rüdiger Mark Skehel Ivan Gout

Alzheimer’s disease (AD) is a neurodegenerative disorder, accounting for at least two-thirds of dementia cases. A combination of genetic, epigenetic and environmental triggers is widely accepted to be responsible for the onset and development of AD. Accumulating evidence shows that oxidative stress and dysregulation of energy metabolism play an important role in AD pathogenesis, leading to neuronal dysfunction and death. Redox-induced protein modifications have been reported in the brain of AD patients, indicating excessive oxidative damage. Coenzyme A (CoA) is essential for diverse metabolic pathways, regulation of gene expression and biosynthesis of neurotransmitters. Dysregulation of CoA biosynthesis in animal models and inborn mutations in human genes involved in the CoA biosynthetic pathway have been associated with neurodegeneration. Recent studies have uncovered the antioxidant function of CoA, involving covalent protein modification by this cofactor (CoAlation) in cellular response to oxidative or metabolic stress. Protein CoAlation has been shown to both modulate the activity of modified proteins and protect cysteine residues from irreversible overoxidation. In this study, immunohistochemistry analysis with highly specific anti-CoA monoclonal antibody was used to reveal protein CoAlation across numerous neurodegenerative diseases, which appeared particularly frequent in AD. Furthermore, protein CoAlation consistently co-localized with tau-positive neurofibrillary tangles, underpinning one of the key pathological hallmarks of AD. Double immunihistochemical staining with tau and CoA antibodies in AD brain tissue revealed co-localization of the two immunoreactive signals. Further, recombinant 2N3R and 2N4R tau isoforms were found to be CoAlated in vitro and the site of CoAlation mapped by mass spectrometry to conserved cysteine 322, located in the microtubule binding region. We also report the reversible H 2 O 2 -induced dimerization of recombinant 2N3R, which is inhibited by CoAlation. Moreover, CoAlation of transiently expressed 2N4R tau was observed in diamide-treated HEK293/Pank1β cells. Taken together, this study demonstrates for the first time extensive anti-CoA immunoreactivity in AD brain samples, which occurs in structures resembling neurofibrillary tangles and neuropil threads. Covalent modification of recombinant tau at cysteine 322 suggests that CoAlation may play an important role in protecting redox-sensitive tau cysteine from irreversible overoxidation and may modulate its acetyltransferase activity and functional interactions.
10 15 2021 739425 10.3389/fncel.2021.739425 1 10.3389/crossmark-policy frontiersin.org true Biotechnology and Biological Sciences Research Council http://dx.doi.org/10.13039/501100000268 Biotechnology and Biological Sciences Research Council http://dx.doi.org/10.13039/501100000268 https://creativecommons.org/licenses/by/4.0/ 10.3389/fncel.2021.739425 https://www.frontiersin.org/articles/10.3389/fncel.2021.739425/full https://www.frontiersin.org/articles/10.3389/fncel.2021.739425/full Neurol. Cent. Alzheimer 25 1906 Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Mol. Cell. Biochem. Bakovic 461 91 2019 A key metabolic integrator, coenzyme A, modulates the activity of peroxiredoxin 5 via covalent modification. 10.1007/s11010-019-03593-w Mol. Simul. Battisti 38 525 2012 Temporary secondary structures in tau, an intrinsically disordered protein. 10.1080/08927022.2011.633347 J. Cell Biol Binder 101 1371 1985 The distribution of tau in the mammalian central nervous system. 10.1083/jcb.101.4.1371 Front. Endocrinol Bourré 9 2018 Direct crosstalk between O-GlcNAcylation and phosphorylation of tau protein investigated by NMR spectroscopy. 10.3389/fendo.2018.00595 J. Nutr. Brass 120 290 1990 Coenzyme A metabolism in vitamin B-12 deficient rats. 10.1093/jn/120.3.290 BMJ Burns 338 467 2009 10.1136/bmj.b158 Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A Castellano 109 15502 2012 Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. 10.1073/pnas.1206446109 Front. Pharmacol Cenini 10 2019 Mitochondria as potential targets in Alzheimer disease therapy: an update. 10.3389/fphar.2019.00902 Front. Physiol. Chew 11 2020 Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. 10.3389/fphys.2020.00598 J. Biomol. Struct. Dyn. Chidambaram 15 1 2020 Role of cysteines in accelerating tau filament formation. 10.1080/07391102.2020.1856720 Nat. Struct. Mol. Biol. Cohen 20 756 2013 The microtubule-associated tau protein has intrinsic acetyltransferase activity. 10.1038/nsmb.2555 Nat. Biotechnol. Cox 26 1367 2008 MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. 10.1038/nbt.1511 Biochem. Soc. Trans Davaapil 42 1056 2014 10.1042/BST20140146 Signalling functions of coenzyme A and its derivatives in mammalian cells. Am. J. Hum. Genet. Dusi 94 11 2014 Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. 10.1016/j.ajhg.2013.11.008 Protein Eng. Des. Sel. Ferrari 31 447 2018 Recombinant production and purification of the human protein tau. 10.1093/protein/gzz010 Nature Fitzpatrick 547 185 2017 10.1038/nature23002 Cryo-EM structures of tau filaments from Alzheimer’s disease. Science Goedert 349 2015 Neurodegeneration. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. 10.1126/science.1255555 Neuron Goedert 1 159 1992 Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. 10.1016/0896-6273(92)90117-v Neuron Goedert 3 519 1989 Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. 10.1016/0896-6273(89)90210-9 J. Neural Transm Gong 112 813 2005 10.1007/s00702-004-0221-0 Post-translational modifications of tau protein in Alzheimer’s disease. Biochem. Soc. Trans. Gout 46 721 2018 Coenzyme A, protein CoAlation and redox regulation in mammalian cells. 10.1042/bst20170506 Biochem. Soc. Trans. Gout 47 469 2019 Coenzyme A: a protective thiol in bacterial antioxidant defence. 10.1042/bst20180415 Proc. Natl. Acad. Sci. U. S. A. Grundke-Iqbal 83 4913 1986 Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. 10.1073/pnas.83.13.4913 Neural Regen. Res. Guo 8 2003 2013 Oxidative stress, mitochondrial damage and neurodegenerative diseases. J. Biol. Chem. Hanger 282 23645 2007 Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. 10.1074/jbc.m703269200 Neuromolecular. Med Hashimoto 4 21 2003 Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. 10.1385/nmm:4:1-2:21 Neuron Hoover 68 1067 2010 tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. 10.1016/j.neuron.2010.11.030 Biomed. Rep Huang 4 519 2016 10.3892/br.2016.630 Role of oxidative stress in Alzheimer’s disease. Nat. Rev. Neurol Iqbal 12 15 2016 Tau and neurodegenerative disease: the story so far. 10.1038/nrneurol.2015.225 Curr. Alzheimer Res. Iqbal 7 656 2010 tau in Alzheimer Disease and Related tauopathies. 10.2174/156720510793611592 Angew. Chem. Int. Ed. Engl. Kadavath 54 10347 2015 Folding of the tau protein on microtubules. 10.1002/anie.201501714 Alzheimers Dement. Kinney 4 575 2018 10.1016/j.trci.2018.06.014 Inflammation as a central mechanism in Alzheimer’s disease. Neuropathol. Appl. Neurobiol Kovacs 41 3 2015 10.1111/nan.12208 Invited review: neuropathology of tauopathies: principles and practice. Biochem. Biophys. Res. Commun. Landino 323 112 2004 Redox modulation of tau and microtubule-associated protein-2 by the glutathione/glutaredoxin reductase system. 10.1016/j.bbrc.2004.08.065 Int. J. Mol. Sci. Lee 21 2020 Neuroprotective effect of antioxidants in the brain. 10.3390/ijms21197152 Annu. Rev. Neurosci Lee 24 1121 2001 10.1146/annurev.neuro.24.1.1121 Neurodegenerative tauopathies. Prog. Lipid Res. Leonardi 44 125 2005 10.1016/j.plipres.2005.04.001 Coenzyme A: back in action. J. Biol. Chem. Lindwall 259 5301 1984 Phosphorylation affects the ability of tau protein to promote microtubule assembly. 10.1016/s0021-9258(17)42989-9 J. Biol. Chem Lipmann 162 743 1946 A common factor in the enzymatic acetylation of sulfanilamide and of choline. 10.1016/s0021-9258(17)41419-0 Mol. Neurodegener Liu 3 2008 tau exon 10 alternative splicing and tauopathies. 10.1186/1750-1326-3-8 Proc. Natl. Acad. Sci. U. S. A Liu 101 10804 2004 O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. 10.1073/pnas.0400348101 Brain J. Neurol. Liu 132 1820 2009 Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. 10.1093/brain/awp099 Biomed. Res. Int. Magi 2016 1 2016 10.1155/2016/6701324 Intracellular Calcium Dysregulation: implications for Alzheimer’s Disease. Biopolym. Cell Malanchuk 31 187 2015 Generation and characterization of monoclonal antibodies specific to Coenzyme A. 10.7124/bc.0008df Front. Cell. Neurosci Mandal 13 2019 Axonal transport and mitochondrial function in neurons. 10.3389/fncel.2019.00373 Neurochem. Int. Martin 58 458 2011 Post-translational modifications of tau protein: implications for Alzheimer’s disease. 10.1016/j.neuint.2010.12.023 Sci. Rep Martinho 8 2018 10.1038/s41598-018-32096-9 Two tau binding sites on tubulin revealed by thiol-disulfde exchanges. Br. J. Cancer McAllister 57 83 1988 The effect of tumour growth on liver pantothenate, CoA, and fatty acid synthetase activity in the mouse. 10.1038/bjc.1988.14 J. Neurochem. Meraz-Rios 112 1353 2010 10.1111/j.1471-4159.2009.06511.x Tau oligomers and aggregation in alzheimer’s disease. Front. Aging Neurosci. Miao 11 2019 Pathological tau from alzheimer’s brain induces site-specific hyperphosphorylation and SDS- and reducing agent-resistant aggregation of tau in vivo. 10.3389/fnagi.2019.00034 Acta Neuropathol Montine 123 1 2012 10.1007/s00401-011-0910-3 National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. J. Biol. Chem Morishima-Kawashima 270 823 1995 Proline-directed and non-proline-directed phosphorylation of PHF-tau. 10.1074/jbc.270.2.823 Cold Spring Harb. Perspect. Biol Nixon 4 2012 Autophagy and neuronal cell death in neurological disorders. 10.1101/cshperspect.a008839 J. Clin. Invest Przedborski 111 3 2003 10.1172/JCI200317522 Neurodegeneration: what is it and where are we? Dev. Dyn. Ramkumar 247 138 2018 ReMAPping the microtubule landscape: how phosphorylation dictates the activities of microtubule-associated proteins. 10.1002/dvdy.24599 Am. J. Physiol. Reibel 240 H606 1981 Regulation of coenzyme A synthesis in heart muscle: effects of diabetes and fasting. Nat. Med. Ross 10 S10 2004 10.1038/nm1066 Protein aggregation and neurodegenerative disease. Proc. Natl. Acad. Sci. U. S. A. Schweers 92 8463 1995 Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. 10.1073/pnas.92.18.8463 Alzheimer’s Disease is The Most Common Neurodegenerative Disorder (Basic Neurochemistry: Molecular, Cellular and Medical Aspects). Selkoe 1999 Nat. Rev. Neurosci. Soto 4 49 2003 Unfolding the role of protein misfolding in neurodegenerative diseases. 10.1038/nrn1007 Biochem. Soc. Trans. Srinivasan 42 1075 2014 Coenzyme A, more than ‘just’ a metabolic cofactor. 10.1042/bst20140125 Biochem. Soc. Trans. Stoker 47 1757 2019 Impact of pharmacological agents on mitochondrial function: a growing opportunity? 10.1042/bst20190280 Acta Neuropathol. Sultana 118 131 2009 Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. 10.1007/s00401-009-0517-0 Biochem. Soc. Trans Theodoulou 42 1025 2014 Coenzyme A and its derivatives: renaissance of a textbook classic. 10.1042/bst20140176 Antioxidants Tossounian 9 2020 The writers, readers, and erasers in redox regulation of GAPDH. 10.3390/antiox9121288 Redox Biol. Tsuchiya 28 2020 Covalent Aurora A regulation by the metabolic integrator coenzyme A. 10.1016/j.redox.2019.101318 J. Biochem. Tsuchiya 474 2489 2017 Protein CoAlation: a redox-regulated protein modification by coenzyme A in mammalian cells. 10.1042/bcj20170129 J. Biochem. Tsuchiya 475 1909 2018 Protein CoAlation and antioxidant function of coenzyme A in prokaryotic cells. 10.1042/bcj20180043 Front. Mol. Neurosci. Vasili 12 2019 Spreading of α-Synuclein and tau: a systematic comparison of the mechanisms involved. 10.3389/fnmol.2019.00107 Proc. Natl. Acad. Sci. U. S. A. Von Bergen 97 5129 2000 Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. 10.1073/pnas.97.10.5129 J. Alzheimers Dis. Wang 33 S123 2013 10.3233/JAD-2012-129031 Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. Mol. Neurodegener. Wang 15 2020 10.1186/s13024-020-00376-6 Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Cell Wesseling 183 1699 2020 tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. 10.1016/j.cell.2020.10.029 Mol. Cell Yang 31 449 2008 Lysine acetylation: codified crosstalk with other posttranslational modifications. 10.1016/j.molcel.2008.07.002 J. Cent. Nerv. Syst. Dis. Yiannopoulou 12 2020 10.1177/1179573520907397 Current and Future Treatments in Alzheimer Disease: an Update. Redox Biol. Yu 44 2021 Regulation of metastasis suppressor NME1 by a key metabolic cofactor coenzyme A. 10.1016/j.redox.2021.101978 Nat. Genet Zhou 28 345 2001 A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. 10.1038/ng572 Data_Sheet_1.PDF 10.3389/fncel.2021.739425.s001 https://www.frontiersin.org/articles/10.3389/fncel.2021.739425/supplementary-material/10.3389/fncel.2021.739425.s001